1 2 microRNAs (miRNAs) are small non-coding RNAs of about 19-25 nt that regulate gene 3 expression post-transcriptionally under various cellular conditions, including apoptosis. The 4 miRNAs involved in modulation of apoptotic events in T cells are partially known. However, 5 heterogeneity associated with cell lines makes it difficult to interpret gene expression signatures 6 especially in cancer-related cell lines. Treatment of Jurkat T cell leukemia cell line with the 7 universal apoptotic drug, camptothecin, resulted in identification of two Jurkat sub-populations: 8
T cells constitute a vital branch of cell-mediated immunity and homeostasis of the 11 immune response is sustained through a balance between proliferation and apoptosis of T cells. 12 A wealth of information has accumulated over the past two decades about the transcriptional 13 regulation of genes mediating apoptosis in T cells. The recent discovery of small RNAs, 14 however, suggests that post-transcriptional gene regulatory networks might have prominent 15 effects on modulation of T cell apoptotic pathways (Lodish et al., 2008; O'Connell et al., 2010) . 16 miRNAs, one of those small RNAs, are non-coding small RNAs of about 19-25 nucleotides in 17 length, which are transcribed by RNA polymerase II (Bartel, 2004; Bartel, 2009) . Followed by 18 nuclear processing by Drosha and cytoplasmic processing by Dicer, the mature miRNA strand 19 negatively regulates gene expression by translational inhibition or destabilization of mRNAs 20 (Miska 2005; Lawrie, 2007; Stefani and Slack, 2008) . miR-14 and bantam were the first 21 members of miRNAs shown to modulate apoptotic functions in Drosophila (Brennecke et al., 22 2003; Xu et al., 2003) . Over the past few years, a clear link has been established between 23 apoptosis and miRNAs (Su et al., 2015) , particularly in cancer development (Kumar et al., 24 2007; Marcucci et al., 2011) . 25 26 Besides the significance of miRNAs in T cell functions, miRNA-mediated T cell 27 apoptosis has also been associated with OncomiRs (Oncogenic miRNAs) in leukemiagenesis 28 (Calin et al., 2009; Pekarsky et al., 2009; Chen et al., 2010) . In fact, miRNA profiling studies 1 particularly on cancerous tissues have clearly shown that each leukemia type (for instance, CLL 2 vs ALL) possesses a prominent miRNA expression signature (Zanette et al., 2007) . Additional 3 studies showed that these miRNAs regulate the expression of apoptotic or anti-apoptotic 4 mRNAs (Mott et al., 2007; Xiao et al., 2008; Akao et al., 2009) . 5 6 Although the use of cell lines has led to the identification of a number of dysregulated 7 miRNAs involved in apoptosis and/or leukemiagenesis (Li et al., 2013; Yamada et al., 2014; 8 Zhou et al., 2014; Fan et al., 2016) , cellular heterogeneity associated with cancerous tissues 9 require careful interpretation of the data acquired from human studies. Cellular heterogeneity is 10 also an important issue that needs to be taken into account while interpreting the data collected 11 from cell lines. It is well documented that cells use cellular heterogeneity to function properly 12 and survive (Benchaouir, 2004; Stockholm et al., 2007; Walling et al., 2012) . Jurkat cells were 13 also reported to be heterogeneous as sublines from the same clones displayed different cellular 14 morphologies and growth patterns (Snow and Judd, 2009) . Although miRNA heterogeneity is 15 known to exist across different cell lines that originate from the same cancer type (Lu et al., 16 2015), the potential for differential miRNA expression across the cells in the same cell line has 17 not been reported before. To identify miRNAs that regulate apoptosis in Jurkat cells and also to 18 test the effect of cellular heterogeneity on drug response and miRNA expression profiles, we 19 triggered apoptosis in Jurkat cells with camptothecin, an inhibitor of DNA topoisomerase I and 20 a potent inducer of apoptosis (Li and Liu, 2001; Pommier et al., 2003) . Following the drug 21 treatment, we sorted the apoptotic sub-population (as defined by Annexin V + ) from the non-22 apoptotic sub-population by magnetic beads. Deep-sequencing of small RNAs isolated from 23 each subpopulation revealed that each sub-population possessed a distinct miRNA expression 24 signature that might be associated with population-specific apoptotic response. Jurkat human leukemic T cells (American Type Culture Collection clone E6.1) were maintained 5 in RPMI 1640 (Gibco) supplemented with 2 mM L-glutamine, 10% fetal bovine serum 6 (GIBCO) and 100 U penicillin/100 µg streptomycin (Biochrom AG) in an atmosphere of 5% 7 CO2 at 37 o C. 10 6 cells were treated with different concentrations of camptothecin (Sigma) and 8 incubated at 37 o C, 5% CO2 to determine the dose kinetics. Cells both in treatment and control 9 group were labeled with PE-conjugated Annexin V and 7AAD (BD Pharmingen) and analyzed 10 by flow cytometry (BD FacsArray) to identify stages of apoptosis. Cells that were Annexin V-11 positive yet 7AAD-negative were defined as early apoptotic ones. Annexin-V-positive cells Total RNA was isolated with mirVana miRNA isolation kit (Ambion) according to the 21 manufacturer's instructions. Total RNA samples were treated with TurboDNase DNA-free kit 22 (Ambion) to remove traces of genomic DNA contamination. RNA integrity was determined by 23 Bioanalyzer (Agilent 2100) using RNA 6000 Nano Kit (average RIN ~ 9-10). Genome Analyzer by Fasteris (Switzerland). The fragments missing either adaptor were 28 excluded from further analyses. The adaptor sequences of bp-15-29 inserts were removed prior 1 to the subsequent data analyses. Nexalign program (Timo, Lassmann, unpublished data, 2 http://genome.gsc.riken.jp/osc/english/software/src/nexalign) was used to align reads to rRNA 3 (NCBI, U133169), hairpin and mature miRNAs (miRBase, R18) (Vaz et al., 2010) . The 4 sequences were aligned first for exact match and then the remaining sequences were used to 5 identify matches with up to three mismatches as described previously (De Hoon et al., 2010) . 6 The data were deposited to GEO under the accession number GSE35442. We first performed dose-response (0.5-1024 µM) kinetics to determine the optimal drug 21 treatment conditions for capturing cells at the apoptotic stage (Annexin V-positive and 7AAD-22 negative). When Jurkat cells were treated with camptothecin for 4h, apoptosis was observed in 23 direct proportion to the dose applied up to 8 µM ( Fig. 1A) . Percentage of apoptotic cells did not (Fig. 1A ). The apparent difference in the apoptotic response could stem either from 7 an uneven exposure of the cells to the drug or from intrinsic resistance of a sub-population to 8 the drug. To ensure that the differential apoptotic capacity of two sub-populations is not due to 9 the uneven drug treatment, we sorted the non-apoptotic cells and re-treated them with the drug. To investigate whether each Jurkat sub-population possesses a distinct miRNA expression 23 profile, we compared the miRNA expression patterns in 3 replicates of each sub-population. 24 The JNN sample contains the Annexin V-negative cells, which were not treated with the drug 25 (negative control) whereas the JAN and JAP samples contain the Annexin V-negative 26 (intrinsically camptothecin-resistant) and positive (intrinsically camptothecin-susceptible) cells, 27 respectively, which were treated with the drug. It should be noted that although the majority of 28 the camptothecin-treated cells were Annexin V-positive and 7AAD-negative prior to sorting, 1 they shifted to a Annexin V/7AAD-double positive phenotype subsequent to sorting. We used 2 the Illumina platform (Fasteris, Switzerland) to quantitatively measure the amounts of small 3 RNAs in each sample. After the removal of the adapter sequences, 91.3% of all reads contained 4 15-29-bp inserts. Based on the size of the inserts, there appeared to be two major small RNA 5 populations, one of 22-23 bp and the other 28 bp, each representing miRNAs and tRNA-derived 6 small RNAs, respectively (Fig. 3) . The alignment of the reads to the known RNAs revealed two 7 striking points with respect to the small RNA content of each sample: (1) the control JNN cells 8 are rich in miRNA, which constitutes 60% of small RNAs. The miRNA content plummets to 26 9 and 16% in the camptothecin-treated JAN and JAP samples, respectively; (2) the drug treatment 10 induces major tRNA fragmentation, constituting up to 45% of all small RNAs ( Fig. 3 ; nt-27-29 11 region). We did not notice a major difference in the proportion of other small RNA categories 12 although there may be differences in the expression of individual small RNAs. 13 14 Apoptosis is regulated by differential miRNA expression 15 16 The alignment of reads to the known miRNAs in miRBase (R18) resulted in identification of 17 184 miRNAs differentially expressed among the three samples (Table 1) . Our list includes the 18 differentially expressed miRNAs, whose expression are greater than 10 RPM (read per million) 19 in all three samples. Thus, the number of differentially expressed genes could be greater. 20 Camptothecin treatment usually suppresses miRNA expression compared to the control cells 21 (Table 2A, sample. More interestingly, a total of 6 miRNAs (let-7b-5p, miR-15a-5p, 324-5p, 128, 425 and 27 720) were reciprocally expressed in the drug-sensitive and resistant cells. To validate our 28 findings from deep-sequencing, we randomly chose 7 miRNAs for validation by real-time 1 qPCR, namely miR-7, 17, 18a, 25, 26a, 93 and 425. As shown in Table 2B , the qPCR results 2 were quite consistent with the deep-sequencing data. identifying several miRNAs involved in cell proliferation or apoptosis (Subramanian and Steer, 10 2010). However, these studies were mainly conducted with heterogenous cancerous tissues in 11 which the apoptotic state of the cells were not synchronized. Thus, we used the Jurkat cell line 12 and the universal apoptosis inducer camptothecin to identify the miRNAs involved in apoptosis. 13 The apoptotic cells were identified by marking the cells in which phosphatidylserine was (Brennecke et al., 2003; Xu et al., 2003) . Studies on various cancer cells showed a prominent 20 p53-mediated regulation of miRNAs, particularly miR-34 family, miR-215 and 192, with pro-21 apoptotic capacity (He et al., 2007; Georges et al., 2008) . However, we did not detect any 22 differential expression of these miRNAs in our study. Let-7 and miR15/16 were also reported to These cells were intrinsically resistant to the drug (Fig. 1F) . To investigate whether the 25 differential apoptotic response of each subpopulation is associated with the differential miRNA 26 expression, we subjected the total RNAs from each subpopulation to deep-sequencing using the 27 un-treated cells as control. There were 79 miRNAs commonly down-regulated in both 28 populations (Table 2A) . Quite interestingly, although some 16 and 30 miRNAs were down-and 1 up-regulated in the drug resistant JAN sample, they were equally expressed in the drug sensitive 2 JAP sample. More interestingly, a total of 6 miRNAs (let-7b-5p, miR-15a-5p, 324-5p, 128, 425 3 and 720) were reciprocally expressed in the drug-sentisive JAP and resistant JAN 4 subpopulations (Table 1 ). This observation suggests that the miRNA expression data obtained 5 from drug treatments should be carefully interpreted if the cells of the desired phenotype are not 6 sorted from the other cells. The presence of the cells with undesired phenotype may introduce 7 noise that may interfere with the accurate assessment of the phenotype-specific miRNA 8 expression profiles. The authors wish to thank the IYTE BIOMER for the instrumental support. This research was 14 supported by a TUBITAK grant 107T475 (to BA). The funder had no role in study design, data 15 collection and analysis, decision to publish or preparation of the manuscript. -miR-128 4,82 -2,94 -7,75 hsa-miR-19b-3p -1,63 -4,34 -2,71 hsa-miR-17-3p 7,14 0,51 -6,62 hsa-miR-19a-3p -1,73 -4,31 -2,59 hsa-miR-720 1,74 -3,42 -5,15 hsa-miR-17-5p -1,59 -3,87 -2,28 hsa-miR-7-5p 3,53 -0,52 -4,05 hsa-miR-20b-5p -1,10 - 0,20 -1,54 -1,75 hsa-miR-30d-3p -1,37 -1,07 0,30 hsa-miR-29c-3p -0,66 -2,41 -1,74 hsa-miR-1277-5p -2,22 -1,88 0,34 hsa-miR-181a-3p -0,36 -1,89 -1,52 hsa-miR-194-5p -2,13 -1,76 0,38 hsa-let-7e-5p -0,72 -2,24 -1,52 hsa-miR-627 -2,09 -1,72 0,38 hsa-miR-219-1-3p 0,53 -0,93 -1,46 hsa-miR-200c-3p -2,41 -1,96 0,45 hsa-miR-27a-3p -0,14 -1,59 -1,45 hsa-miR-500a-5p -1,05 -0,57 0,48 hsa-let-7c 0,22 -1,21 -1,43 hsa-miR-93-3p -1,42 -0,90 0,52 hsa-miR-98 -0,21 -1,63 -1,42 hsa-miR-146a-5p -3,25 -2,72 0,53 hsa-miR-942 0,24 -1,17 -1,41 hsa-miR-320b -1,52 -0,94 0,57 hsa-miR-7-1-3p 0,12 -1,25 -1,38 hsa-miR-9-3p -1,39 -0,73 0,66 hsa-let-7f-5p 0,10 -1,19 -1,29 hsa-miR-374a-3p -2,08 -1,42 0,66 hsa-miR-181a-2-3p 0,31 -0,98 -1,28 hsa-miR-320c -1,59 -0,88 0,71 hsa-miR-652-3p 0,44 -0,78 -1,22 hsa-miR-450b-5p -1,78 -1,04 0,74 hsa-miR-548b-5p 0,90 -0,31 -1,21 hsa-miR-320d -1,04 -0,24 0,79 hsa-miR-9-5p 0,57 -0,61 -1,18 hsa-miR-542-3p -1,44 -0,62 0,83 hsa-miR-93-5p 0,09 -1,08 -1,17 hsa-miR-629-3p -1,24 -0,38 0,86 hsa-miR-760 0,81 -0,33 -1,14 hsa-miR-148b-3p -3,28 -2,36 0,92 hsa-miR-184 0,96 -0,15 -1,12 hsa-miR-340-3p -1,36 -0,44 0,93 hsa-miR-151a-3p -0,30 -1,32 -1,01 hsa-miR-339-5p -1,34 -0,27 1,07 hsa-miR-95 0,01 -1,00 -1,01 hsa-miR-345-5p -1,41 -0,30 1,11 hsa-miR-152 0,12 -0,88 -1,01 hsa-miR-342-3p -2,72 -1,60 1,11 hsa-miR-501-3p -0,40 -1,26 -0,86 hsa-miR-126-3p -1,96 -0,78 1,18 hsa-miR-27b-5p -0,29 -1,07 -0,78 hsa-miR-193b-3p -2,05 -0,82 1,23 hsa-miR-15b-3p -0,55 -1,33 -0,77 hsa-miR-363-3p -2,82 -1,55 1,27 hsa-miR-30e-3p -0,40 -1,13 -0,73 hsa-miR-361-5p -6,52 -5,24 1,28 hsa-miR-203 -0,36 -1,04 -0,69 hsa-miR-126-5p -2,77 -1,42 1,36 hsa-miR-340-5p -0,82 -1,34 -0,52 hsa-miR-769-5p -3,28 -1,87 1,41 hsa-miR-196a-5p -0,99 -1,39 -0,40 hsa-miR-140-5p -6,36 -4,74 1,61 hsa-miR-625-5p -0,88 -1,19 -0,31 hsa-miR-30c-5p -4,80 -2,90 1,90 hsa-miR-580 -0,85 -1,13 -0,29 hsa-miR-455-3p -1,37 0,66 2,03 hsa-miR-454-5p -0,93 -1,01 -0,08 hsa-let-7g-5p -6,14 -3,78 2,37 hsa-miR-1292 -1,00 -1,02 -0,02 hsa-miR-186-5p -5,45 -2,80 2,65 hsa-miR-1248 0,06 1,03 0,97 hsa-miR-24-3p -3,48 -0,81 2,67 hsa-miR-181a-5p -0,81 0,31 1,13 hsa-miR-142-5p -6,58 -3,89 2,70 hsa-miR-32-5p -3,12 -0,11 3,01 hsa-miR-142-3p -4,60 -1,08 3,52 hsa-miR-766-3p -4,79 -1,05 3,74 hsa-miR-425-5p -2,48 1,74 4,22 1 2 3 4 5 6 
